This revealed a previously unappreciated interaction between MARCH5 and MCL1 inhibitors, with potential utility to derive predictive models of MCL1 inhibitor response across multiple cancer types, and particularly in solid tumours such as breast carcinomas. Here, MARCHF5 is linked to breast carcinoma.